NCT03578081 2025-04-06
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Alliance for Clinical Trials in Oncology
Phase 3 Completed
Clinical Trials
6 trialsNCT02780609 2022-11-04
Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Completed
NCT01504711 2021-04-08
Fosaprepitant Dimeglumine in Preventing Nausea and Vomiting in Patients With Gastrointestinal Cancer Receiving Combination Chemotherapy
Barbara Ann Karmanos Cancer Institute
Phase NA Completed
NCT01432015 2017-03-28
Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting
Gynecologic Oncology Associates
Phase 4 Completed
NCT01736917 2016-05-25
Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Germ Cell Tumors
Hoosier Cancer Research Network
Phase 2 Completed
NCT01490060 2016-04-11
Fosaprepitant in Patients Receiving Ifosfamide-based Regimen
M.D. Anderson Cancer Center
Phase NA Completed